0001437749-23-028701.txt : 20231023
0001437749-23-028701.hdr.sgml : 20231023
20231023060605
ACCESSION NUMBER: 0001437749-23-028701
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231020
FILED AS OF DATE: 20231023
DATE AS OF CHANGE: 20231023
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: TATE JEFFREY
CENTRAL INDEX KEY: 0001499075
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39780
FILM NUMBER: 231338438
MAIL ADDRESS:
STREET 1: C/O CTD HOLDINGS, INC.
STREET 2: 27317 NW 78TH AVENUE
CITY: HIGH SPRINGS
STATE: FL
ZIP: 32643
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cyclo Therapeutics, Inc.
CENTRAL INDEX KEY: 0000922247
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 593029743
STATE OF INCORPORATION: FL
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6714 NW 16TH STREET, SUITE B
CITY: GAINESVILLE
STATE: FL
ZIP: 32653
BUSINESS PHONE: 386-418-8060
MAIL ADDRESS:
STREET 1: PO BOX 1180
CITY: ALACHUA
STATE: FL
ZIP: 32616-1180
FORMER COMPANY:
FORMER CONFORMED NAME: CTD HOLDINGS INC
DATE OF NAME CHANGE: 20000913
FORMER COMPANY:
FORMER CONFORMED NAME: CYCLODEXTRIN TECHNOLOGIES DEVELOPMENT INC
DATE OF NAME CHANGE: 19941012
4
1
rdgdoc.xml
FORM 4
X0508
4
2023-10-20
0000922247
Cyclo Therapeutics, Inc.
CYTH
0001499075
TATE JEFFREY
C/O CYCLO THERAPEUTICS, INC.
6714 NW 16TH STREET, SUITE B
GAINESVILLE
FL
32163
1
1
Chief Operating Officer
0
Common Stock
2023-10-20
4
X
0
29941
0.71
A
92042
D
Warrant to Purchase Common Stock
0.71
2023-10-20
4
X
0
29941
0.125
D
2023-04-20
2030-04-20
Common Stock
29941
0
D
Warrant to Purchase Common Stock
0.95
2023-10-20
4
P
0
32935
A
2023-10-20
2027-10-20
Common Stock
32935
32935
D
The Reporting Person exercised vested Warrants (the "Original Warrants") to purchase 29,941 shares of the Issuer's common stock pursuant to a Securities Purchase Agreement dated October 20, 2023 ("Closing Date"). The Reporting Person exercised his Original Warrant in full on or prior to the Closing Date in consideration of the receipt of new warrants with an exercise price equal to $0.95 per share, to purchase 110% of the shares of the Issuer's common stock covered under the Original Warrants.
/s/ Jeffrey Tate
2023-10-23